Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone506 2434 2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$61.21 million
Profitability
Miscellaneous
Employees505
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Establishment Labs (NASDAQ:ESTA) Frequently Asked Questions
What is Establishment Labs' stock symbol?
Establishment Labs trades on the NASDAQ under the ticker symbol "ESTA."
How were Establishment Labs' earnings last quarter?
Establishment Labs Holdings Inc (NASDAQ:ESTA) issued its earnings results on Tuesday, August, 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.08. The firm had revenue of $21.68 million for the quarter, compared to the consensus estimate of $20.10 million. Establishment Labs had a negative net margin of 38.63% and a negative return on equity of 60.43%. View Establishment Labs' Earnings History.
When is Establishment Labs' next earnings date?
What guidance has Establishment Labs issued on next quarter's earnings?
Establishment Labs issued an update on its FY 2019 earnings guidance on Tuesday, August, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $84-86 million, compared to the consensus revenue estimate of $84.4 million.
What price target have analysts set for ESTA?
3 brokers have issued 1-year target prices for Establishment Labs' shares. Their predictions range from $29.00 to $40.00. On average, they expect Establishment Labs' stock price to reach $35.33 in the next twelve months. This suggests a possible upside of 90.2% from the stock's current price. View Analyst Price Targets for Establishment Labs.
What is the consensus analysts' recommendation for Establishment Labs?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Establishment Labs.
What are Wall Street analysts saying about Establishment Labs stock?
Here are some recent quotes from research analysts about Establishment Labs stock:
- 1. According to Zacks Investment Research, "Establishment Labs Holdings Inc. is a medical technology company. It focuses on designing, developing, manufacturing and marketing portfolio of silicone gel-filled breast implants ae well as body shaping implants. The company's brand consists of Motiva Implants(R) and MotivaImagine (R) platform. Its technologies portfolio includes Divina 3D Simulation System(R), Puregraft and MotivaImagine Centers (R). Establishment Labs Holdings Inc. is based in NEW YORK. " (10/15/2019)
- 2. BTIG Research analysts commented, "Establishment reported impressive Q1 sales of ~$21M, besting consensus of $18M. Heading into the quarter, we felt there was a very strong likelihood of a beat but the magnitude of the sequential bump (27%) was surprising. We are encouraged that quarterly improvement was spurred by strong underlying demand in W. Europe, Brazil, and S. Korea – less so, it seems from any pull forward benefit in Q1. Even with a strong start, guidance was set at $80-84M for FY19, implying little improvement over Q1 results. We understand the conservatism around quarterly lumpiness and seasonality, but we still see a few areas that can drive upside, particularly in the second half: 1) the ramp in 2) ongoing transition to direct sales, and 3) share gains in W. Europe following the fall-out of textured implants. We model FY19 revenue above guidance at $86M." (5/16/2019)
Has Establishment Labs been receiving favorable news coverage?
Press coverage about ESTA stock has been trending somewhat positive on Monday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Establishment Labs earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Establishment Labs.
Are investors shorting Establishment Labs?
Establishment Labs saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 580,200 shares, a decline of 9.4% from the August 30th total of 640,100 shares. Based on an average daily trading volume, of 84,600 shares, the days-to-cover ratio is currently 6.9 days. Currently, 3.7% of the shares of the stock are sold short. View Establishment Labs' Current Options Chain.
Who are some of Establishment Labs' key competitors?
Some companies that are related to Establishment Labs include Inogen (INGN), Sientra (SIEN), Invacare (IVC), RTI Surgical (RTIX), ConforMIS (CFMS), Lakeland Industries (LAKE), Histogenics (HSGX), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), Precision Therapeutics (POAI), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Allied Healthcare Products (AHPI), Bionik Laboratories (BNKL) and Ocugen (OCGN).
What other stocks do shareholders of Establishment Labs own?
Who are Establishment Labs' key executives?
Establishment Labs' management team includes the folowing people:
- Mr. Juan Jose Chacon Quiros, Founder, CEO & Exec. Director (Age 47)
- Mr. Salvador Santos Dada, Chief Operating Officer (Age 37)
- Mr. Eddie De Oliveira, VP of Sales, Brazil (Age 36)
- Ms. Renee M. Gaeta, Chief Financial Officer (Age 38)
- Mr. Roberto De Mezerville, Chief Technology Officer (Age 39)
When did Establishment Labs IPO?
(ESTA) raised $50 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen served as the underwriters for the IPO and BTIG was co-manager.
Who are Establishment Labs' major shareholders?
Establishment Labs' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Berkshire Asset Management LLC PA (0.06%). Company insiders that own Establishment Labs stock include David L Bonvenuto, Jw Asset Management, Llc and Nicholas Sheridan Lewin. View Institutional Ownership Trends for Establishment Labs.
Which major investors are buying Establishment Labs stock?
ESTA stock was bought by a variety of institutional investors in the last quarter, including Berkshire Asset Management LLC PA. Company insiders that have bought Establishment Labs stock in the last two years include David L Bonvenuto, Jw Asset Management, Llc and Nicholas Sheridan Lewin. View Insider Buying and Selling for Establishment Labs.
How do I buy shares of Establishment Labs?
Shares of ESTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Establishment Labs' stock price today?
One share of ESTA stock can currently be purchased for approximately $18.58.
How big of a company is Establishment Labs?
Establishment Labs has a market capitalization of $380.89 million and generates $61.21 million in revenue each year. The company earns $-21,100,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Establishment Labs employs 505 workers across the globe.View Additional Information About Establishment Labs.
What is Establishment Labs' official website?
How can I contact Establishment Labs?
Establishment Labs' mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The company can be reached via phone at 506 2434 2400 or via email at [email protected]
MarketBeat Community Rating for Establishment Labs (NASDAQ ESTA)
MarketBeat's community ratings are surveys of what our community members think about Establishment Labs and other stocks. Vote "Outperform" if you believe ESTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
